Shares of Vera Therapeutics (NASDAQ:VERA) climbed 6% on Monday as traders and investors reacted to an upcoming regulatory deadline. The U.S. Food and Drug Administration is scheduled to issue a decision on July 7 under the Prescription Drug User Fee Act regarding the company's Biologics License Application seeking accelerated approval for atacicept in adults with IgA nephropathy, or IgAN.
Atacicept is described by the company as an investigational soluble recombinant fusion protein that targets two cytokines, B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). Those cytokines are implicated in promoting B-cell survival and the production of autoantibodies associated with IgAN, according to company disclosures.
Vera Therapeutics announced in June that it had reached agreement with the FDA on a revised analysis plan for the ORIGIN 3 trial's estimated glomerular filtration rate, or eGFR, results. The company said those ORIGIN 3 eGFR results are now expected in the third quarter of 2026, moved forward from an earlier projection of 2027. Contingent on a positive eGFR analysis, Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026, with a potential pathway to full approval in 2027.
The ORIGIN Phase 3 program previously met its primary endpoint in a prespecified interim analysis, showing a statistically significant reduction in proteinuria at week 36. Earlier-stage data from the ORIGIN Phase 2b trial also met its primary and key secondary endpoints, with reductions in proteinuria and stabilization of eGFR compared with placebo through 36 weeks.
Regulatory designations and clinical exposure are part of the program's profile: atacicept has been granted Breakthrough Therapy Designation by the FDA for the treatment of IgAN, and the investigational therapy has been administered to more than 1,500 patients across clinical trials in various disease areas.
Summary
Vera Therapeutics' stock reacted to an approaching July 7 FDA PDUFA decision on atacicept for adults with IgAN. The company has moved forward the timeline for ORIGIN 3 eGFR results to the third quarter of 2026 and outlined plans for a supplemental filing and potential full approval pending favorable outcomes.
Key points
- Stock movement: Vera shares rose 6% on Monday ahead of the July 7 PDUFA date, reflecting investor focus on regulatory outcomes - sectors impacted include biotech and healthcare equities.
- Regulatory path: The FDA will decide on a BLA seeking accelerated approval for atacicept in adults with IgAN; the drug holds Breakthrough Therapy Designation.
- Data and timelines: ORIGIN Phase 3 met its interim primary endpoint for proteinuria reduction at week 36; ORIGIN 3 eGFR results are now expected in Q3 2026, accelerating the prior timeline and enabling a potential sBLA submission in Q4 2026 and possible full approval in 2027 - implications extend to pharmaceutical development and clinical trial planning.
Risks and uncertainties
- Regulatory risk: The FDA decision on July 7 could go either way, and accelerated approval is not guaranteed - this directly affects biotech investors and markets tied to regulatory outcomes.
- Data dependency: Vera's plans for an sBLA and potential full approval hinge on a positive ORIGIN 3 eGFR analysis expected in Q3 2026; unfavourable results could delay or derail those plans, impacting clinical development and investor sentiment.
- Clinical variability: While Phase 2b and a Phase 3 interim analysis met key endpoints through 36 weeks, longer-term and broader data will be necessary to support full approval - this uncertainty affects healthcare payers and market uptake considerations.